Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Ani Pharmaceuticals Q3 2026 Results: Net Income $35.1M, Up 32.1% YoY

ANI Pharmaceuticals reported a significant improvement in financial position for the period ended September 30, 2026, shifting from an accumulated deficit of $23.1 million to retained earnings of $66.3 million. Total assets increased to $1.57 billion, driven by a substantial rise in cash and cash equivalents to $420.8 million, while the company continues to focus on strategic growth through the proposed acquisition of Egetis Therapeutics AB.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue290.8227.8
Profit before tax49.033.8
Net income35.126.6
EPS (diluted, $ a share)$1.51$1.13

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+32.1%
Revenue, year on year+27.6%
Operating margin18.0%
Source

10-Q filed with the SEC, NASDAQ: ANIP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Ani Pharmaceuticals Inc: key numbers

Share price
$70.89Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Ani Pharmaceuticals Inc

All →
8:01 AM ET 8-K
Investor Presentation

Ani Pharmaceuticals Investor Presentation

ANI Pharmaceuticals published an updated corporate investor presentation for November 2026 to its website. The presentation outlines the company's strategic transformation into a leading rare disease company, including its proposed acquisition of Egetis Therapeutics and growth strategies for products like Cortrophin Gel and ILUVIEN.

4:36 PM ET Form 4
Insider Selling

Ani Pharmaceuticals Sr. VP, General Counsel & Sec. Meredith Cook Sells $35.4K of Stock

Meredith Cook, Sr. VP, General Counsel & Sec., sold 500 shares of Ani Pharmaceuticals Inc at $70.80 a share, worth $35.4K in total on Nov 13, 2026. Shares held after the trade: 72,924 (-0.7%).

Value
$35.4K
Shares
500
Price
$70.80
Role
Sr. VP, General Counsel & Sec.
Holding change
-0.7%
Trade date
Nov 13, 2026
5:13 PM ET 8-K
M&A Deal

Ani Pharmaceuticals Signs $676M M&A Deal with Egetis Therapeutics AB

ANI Pharmaceuticals announced a recommended public cash offer to acquire all outstanding shares, convertibles, and warrants of Sweden-based Egetis Therapeutics AB. To finance the acquisition and refinance existing debt, ANI entered into a $676 million 364-day senior bridge credit facility with JPMorgan Chase Bank. The offer price is set at SEK 11.25 per share in cash.

Value
$676M
Counterparty
Egetis Therapeutics AB (publ)
6:57 AM ET 8-K
Financial Results

Ani Pharmaceuticals Financial Results

ANI Pharmaceuticals reported Q3 2026 net revenues of $290.8 million, a 27.6% year-over-year increase driven by strong performance in its Rare Disease and Generics segments. The company narrowed its full-year revenue guidance and raised its adjusted EBITDA and EPS outlook while highlighting its pending acquisition of Egetis Therapeutics.

Term
Q3 2026

“In the third quarter, ANI delivered strong financial results, while advancing our transformation into a leading Rare Disease company. Cortrophin Gel delivered solid growth, driven by momentum from the gout expansion and continued progress in our existing specialties, while our Generics business continued to outperform.”

Nikhil Lalwani, President and CEO of ANI

“As we head into the end of the year, we are focused on delivering our 2026 financial guidance and advancing the proposed acquisition of Egetis toward closing. We are also executing multiple operational and strategic initiatives to achieve approximately 40% year-over-year growth in 2026 for Cortrophin and capture the significant multi-year growth opportunity ahead.”

Nikhil Lalwani, President and CEO of ANI
4:36 PM ET Form 4
Insider Selling

Ani Pharmaceuticals SVP & CFO Stephen P. Carey Sells $208K of Stock

Stephen P. Carey, SVP & CFO, sold 2,850 shares of Ani Pharmaceuticals Inc at $72.87 a share, worth $208K in total on Oct 29, 2026. Shares held after the trade: 166,143 (-1.7%).

Value
$208K
Shares
2,850
Price
$72.87
Role
SVP & CFO
Holding change
-1.7%
Trade date
Oct 29, 2026
6:50 PM ET Form 4
Insider Selling

Ani Pharmaceuticals President & CEO Nikhil Lalwani Sells $388K of Stock

Nikhil Lalwani, President & CEO, sold 5,400 shares of Ani Pharmaceuticals Inc at $71.89 a share, worth $388K in total on Oct 15, 2026. Shares held after the trade: 333,689 (-1.6%).

Value
$388K
Shares
5,400
Price
$71.89
Role
President & CEO
Holding change
-1.6%
Trade date
Oct 15, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.